Nuvation reroutes its glioma plan
The company will no longer initiate a head-to-head trial of safusidenib against Voranigo.
Merck gets two Welireg wins
The second-line Litespark-011 and adjuvant Litespark-022 trials are apparently hits.
Novartis trips over the Hippo
The company discontinues its Yap/TEAD inhibitor IAG933 owing to lack of tolerability and efficacy.
Triple meeting 2025 – Halda’s proximity play in prostate
Early data with the RIPTAC HLD-0915 look competitive.
Triple meeting 2025 – early efficacy signs for Quanta
The G12D-preferring QTX3034 has produced responses in endometrial and colorectal cancers.
Tango waltzes towards phase 3
The company plans a pivotal pancreatic cancer trial after seeing two responses in eight patients.
GSK prepares its kit in GIST
The company advances the IDRx-originated KIT inhibitor GSK6042981 into pivotal trials.
Triple meeting 2025 – Revolution hints at post-KRAS promise
The G12C-selective elironrasib produces a 42% ORR in post-Lumakras/Krazati patients.
ESMO 2025 – Incyte impresses in KRAS G12D
Response rates with INCB161734 in pancreatic cancer look in line with Revolution.
